Upcoming Trials for mHSPC and mCRPC and Next-Generation Sequencing

5 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
In the fifth segment of this roundtable series, David Morris, MD, FACS; John Phillips, MD; Jeremy McDuffie, MD; Katy Beckermann, MD, PhD; and Alan Tan, MD, explore the promise of next-generation sequencing, PARP inhibitors, and T-cell engagers for prostate cancer treatment, highlighting their role in precision medicine. The experts share their practical workflows for utilizing tissue and liquid biopsies, examine the evolving landscape of radioligand therapies like lutetium-177 PSMA and radium, and discuss emerging biomarkers and treatment combinations.

#prostatecancer #prostatecarcinoma #oncology #cancer #cancerresearch #healthcare
Category
Oncology
Be the first to comment

Up Next